These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12412479)

  • 1. Recombinant single-chain and disulfide-stabilized Fv immunotoxins for cancer therapy.
    Niv R; Segal D; Reiter Y
    Methods Mol Biol; 2003; 207():255-68. PubMed ID: 12412479
    [No Abstract]   [Full Text] [Related]  

  • 2. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.
    Reiter Y; Brinkmann U; Lee B; Pastan I
    Nat Biotechnol; 1996 Oct; 14(10):1239-45. PubMed ID: 9631086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of recombinant immunotoxins for specific targeting of tumor-related peptides presented by MHC molecules.
    Cohen CJ; Denkberg G; Segal D; Reiter Y
    Methods Mol Biol; 2003; 207():269-82. PubMed ID: 12412480
    [No Abstract]   [Full Text] [Related]  

  • 4. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.
    Reiter Y; Brinkmann U; Webber KO; Jung SH; Lee B; Pastan I
    Protein Eng; 1994 May; 7(5):697-704. PubMed ID: 8073039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.
    Reiter Y; Brinkmann U; Kreitman RJ; Jung SH; Lee B; Pastan I
    Biochemistry; 1994 May; 33(18):5451-9. PubMed ID: 7910034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
    Reiter Y; Pastan I
    Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD7-specific single chain Fv immunotoxins. Design and expression.
    Pennell CA; Pauza ME
    Methods Mol Biol; 2001; 166():17-29. PubMed ID: 11217366
    [No Abstract]   [Full Text] [Related]  

  • 9. Generation and characterization of bispecific tandem diabodies for tumor therapy.
    Kipriyanov SM
    Methods Mol Biol; 2003; 207():323-33. PubMed ID: 12412483
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
    Hao HJ; Jiang YQ; Zheng YL; Ma R; Yu DW
    Biochimie; 2005 Aug; 87(8):661-7. PubMed ID: 15927340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies.
    Kurucz I; Titus JA; Jost CR; Segal DM
    Mol Immunol; 1995 Dec; 32(17-18):1443-52. PubMed ID: 8643113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins.
    Niv R; Cohen CJ; Denkberg G; Segal D; Reiter Y
    Curr Pharm Biotechnol; 2001 Mar; 2(1):19-46. PubMed ID: 11482347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotoxin therapy of cancer.
    Pastan I; Hassan R; Fitzgerald DJ; Kreitman RJ
    Nat Rev Cancer; 2006 Jul; 6(7):559-65. PubMed ID: 16794638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro characterization of a recombinant 32P-phosphorylated anti-(carcinoembryonic antigen) single-chain antibody.
    Patrick MR; Chester KA; Pietersz GA
    Cancer Immunol Immunother; 1998 Jun; 46(4):229-37. PubMed ID: 9671146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxins and cancer therapy.
    Li Z; Yu T; Zhao P; Ma J
    Cell Mol Immunol; 2005 Apr; 2(2):106-12. PubMed ID: 16191416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and characterization of human CD7-specific single-chain Fv immunotoxins.
    Pauza ME; Doumbia SO; Pennell CA
    J Immunol; 1997 Apr; 158(7):3259-69. PubMed ID: 9120282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis.
    Reiter Y; Pastan I
    Trends Biotechnol; 1998 Dec; 16(12):513-20. PubMed ID: 9881483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly.
    Wörn A; Plückthun A
    FEBS Lett; 1998 May; 427(3):357-61. PubMed ID: 9637257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli.
    Glockshuber R; Schmidt T; Plückthun A
    Biochemistry; 1992 Feb; 31(5):1270-9. PubMed ID: 1736986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy.
    Hombach A; Heuser C; Abken H
    Methods Mol Biol; 2003; 207():365-81. PubMed ID: 12412486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.